$14.06
-0.18 (-1.26%)
Open$14.13
Previous Close$14.24
Day High$14.35
Day Low$13.83
52W High$28.00
52W Low$8.36
Volume—
Avg Volume860.5K
Market Cap958.41M
P/E Ratio—
EPS$-2.84
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+160.8% upside
Current
$14.06
$14.06
Target
$36.67
$36.67
$19.65
$36.67 avg
$47.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 85.08M | 76.59M | 82.32M |
| Net Income | 21.83M | 19.00M | 17.76M |
| Profit Margin | 25.7% | 24.8% | 21.6% |
| EBITDA | 33.39M | 28.41M | 32.89M |
| Free Cash Flow | 16.91M | 11.51M | 18.65M |
| Rev Growth | +15.3% | +2.7% | +8.4% |
| Debt/Equity | 0.18 | 0.16 | 0.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |